Traders Digest Nvidia Earnings, Upward Revision in Q2 Growth Data as US Equity Futures Rise Pre-Bell

MT Newswires Live08-29

US equity futures rose ahead of Thursday's opening bell as traders digested quarterly earnings from chipmaker Nvidia (NVDA) and a batch of economic data.

Dow Jones Industrial Average futures rose 0.7%, S&P 500 futures gained 0.3%, and Nasdaq futures were up 0.2%.

Nvidia reported late Wednesday higher fiscal Q2 adjusted earnings and revenue that topped analysts' estimates.

Oil prices were higher, with front-month global benchmark North Sea Brent crude up 0.6% at $78.08 per barrel and US West Texas Intermediate crude up 0.9% at $75.22 per barrel.

US gross domestic product, released at 8:30 am ET, was upwardly revised to 3% growth in the second estimate for Q2 from the first estimate of 2.8%, compared with projections compiled by Bloomberg for no revision.

The advance international trade in goods deficit, also released at 8:30 am ET, widened to $102.66 billion in July from $96.56 billion in the previous month, compared with estimates for a $97.8 billion gap. Weekly jobless claims dropped to 231,000 in the week ended Aug. 24 from 233,000 claims in the prior week, versus estimates for a smaller drop to 232,000.

Pending home sales, due at 10 am ET, is seen rising 0.2% in July versus June's 4.8% increase.

In other world markets, Japan's Nikkei closed 0.02% lower, Hong Kong's Hang Seng ended 0.5% higher, and China's Shanghai Composite finished 0.5% lower. Meanwhile, UK's FTSE 100 rose 0.5%, and Germany's DAX 30 index increased 0.6%, France's CAC 40 increased 0.8% and Spain's IBEX 35 increased 0.4% in Europe's early afternoon session.

In equities, shares of Dollar General (DG) were 26% lower pre-bell after the company lowered its fiscal 2024 guidance. Pure Storage (PSTG) shares dropped 12% after the company issued fiscal 2025 revenue guidance that trailed analysts' projections.

On the winning side, BioCardia (BCDA) shares were up over 96% after the company said overnight it secured the US Food and Drug Administration clearance for its Morph DNA Steerable Introducer product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment